TrialBlood advances2021

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.

Naveen Pemmaraju et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.